Autologous peripheral blood stem cell transplant

PROCEDURE2 trials

Sponsors

Columbia University, Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Conditions

Leukemia, Myeloid, AcuteMultiple Myeloma

Phase 2

Risk-adapted Therapy for Primary Acute Myeloid Leukemia

CompletedNCT04687098

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y MielodisplasiasLeukemia, Myeloid, Acute

Start: 2012-02-01End: 2022-11-10Updated: 2023-06-27

Phase 4

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

CompletedNCT01731886

Columbia UniversityMultiple Myeloma

Start: 2012-09-30End: 2017-04-11Updated: 2020-02-05

Related Papers

Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

Blood Cancer Journal2023-05-0517 citations

P565: IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY

HemaSphere2022-06-01

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Blood2015-12-03

Lenalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a randomized, phase III trial.

Journal of Clinical Oncology2015-05-20